Experience

IMMvention Therapeutix, Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Executive Officer & Board Director

  • Dec 2017 - Present

  Raleigh-Durham, North Carolina Area IMMvention Therapeutix (launched from UNC-Chapel Hill) is a venture capital funded company discovering and developing novel small molecule disease modifying therapies for rare and prevalent inflammatory diseases caused by activation of the inflammasomes.



OpenDoors Group

• United States
• Non-profit Organizations

• Co-Founder

  • Jan 2019 - Present

  Durham, North Carolina, United States



Enzerna Biosciences

• Board Of Directors

  • Feb 2019 - Present

  Chapel Hill, NC Enzerna is pioneering genetic medicines (gene therapy) with its RNA-editing platform for nucleotide repeat disorders (including Huntington's disease, and certain forms of ALS). https://www.enzerna.com/



OpenDoors Group, LLC

• CEO/CBO at Biotechnology Companies

  • Apr 2016 - Dec 2020

  Chapel Hill, NC Consulting practice to deliver customized expertise in strategic planning, business development, roadshow/pitch-deck, opening doors into pharma, structuring and negotiating deals, raising capital from VCs, Corp VCs and non-dilutive sources. Currently working with three private biotechnology companies as: • CEO & Board member at IMMvention Therapeutix. Innate immunity platform startup from UNC-Chapel Hill • CBO at MimiVax, LLC. Phase 2 clinical stage immuno-oncology (neo-antigen… Show more Consulting practice to deliver customized expertise in strategic planning, business development, roadshow/pitch-deck, opening doors into pharma, structuring and negotiating deals, raising capital from VCs, Corp VCs and non-dilutive sources. Currently working with three private biotechnology companies as: • CEO & Board member at IMMvention Therapeutix. Innate immunity platform startup from UNC-Chapel Hill • CBO at MimiVax, LLC. Phase 2 clinical stage immuno-oncology (neo-antigen, mAb & CAR-T programs) • CBO at NovaTarg, a novel AMPK activators for polycystic kidney disease and diabetes Recent Companies • Ribometrix, Inc. RNA/Small molecule platform company. Led strategy/roadshow for successful Seed funding ($7.5M Oct’17) from SV Health, Hatteras VP, AbbVie, MPH Healthcare, & Alexandria Ventures • Bantam Pharmaceutical. Pre-IND stage cancer metabolism therapeutics company • Symberix. Seed stage startup from UNC-Chapel Hill with small molecule/microbiome platform • Kymera, Inc. Atlas, Lilly, Amgen venture funded - Novel therapeutics platform/protein degradation • Sofusa (division of Kimberly-Clark). Drug delivery device division for CNS, RA, immuno-oncology • Esanex Pharma, Inc. VC funded (InterSouth, Lilly Ventures, Takeda Ventures, Ritchie Capital) Phase 2 oncology company spun off from Pfizer. Led partnering strategy, pitch-deck development and marketing to potential pharma partners Show less



Ribometrix Inc.

• United States
• Biotechnology Research
• 1 - 100 Employee

• Chief Operating Officer

  • Jun 2016 - Aug 2017

  Raleigh-Durham, North Carolina Area



NightHawk Biosciences, Inc

• United States
• Biotechnology Research
• 1 - 100 Employee

• Vice President of Business Development

  • Dec 2013 - Apr 2016

  Durham, NC, USA • Developed global strategic partnering plan, managed entire process from first contact with pharma & biotechs • Advanced multiple partnering term sheets with pharma and big biotech



Qualiber, Inc.

• President, CEO and Co-Founder

  • Apr 2010 - Dec 2013

  Chapel Hill, NC • Co-founded/established company with scientific founder • Secured ~$1.5M non-dilutive funding from NIH/NCI, NC Biotech Center, Carolina KickStart program



Optherion, Inc

• Vice President, Business Development

  • Mar 2009 - Feb 2010

  New Haven, CT Domain Associates, Johnson & Johnson Development Corporation, Purdue Pharmaceutical Products L.P., Pappas Ventures, Biogen Idec New Ventures, and GE Healthcare Financial Services funded company. • Led the structuring and negotiations for WW out-license to Sequenom



Serenex

• Biotechnology Research
• 1 - 100 Employee

• Vice President, Business Development

  • Jul 2003 - May 2008

  Durham, NC VC (InterSouth Partners, Lilly Ventures, Takeda Ventures, Richie Capital) funded oncology company. • Led strategic business development plan culminating in acquisition of Serenex by Pfizer.



Takeda Oncology

• United States
• Pharmaceutical Manufacturing
• 700 & Above Employee

• Senior Manager, Corporate Development

  • 1999 - 2003

  Cambridge, MA Completed many many deals progressing Millennium from genomics based discovery to a clinical stage company



Genome Therapeutics Corporation

• Biotechnology
• 1 - 100 Employee

• Manager, Business Development

  • 1996 - 1999

  Waltham, MA started my deal making career!



Center for Agriculture and Environment

• Post Doctoral Fellow

  • Nov 1993 - Sep 1996

  Environmental Microbiology, Molecular Pathways and Bioremediation Biotransformations



Merck and Co

• Post Doctoral Fellow

  • 1993 - 1993

  Can't tell (it's confidential)